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1. Introduction 
Nicotine, named after the French diplomat Jean Nicot who brought the tobacco plant 
(Nicotiana tabacum) to France, isolated in 1828 as the major pharmacologically active 
compound in this plant (Posselt & Reimann, 1828), structurally identified between 1890 and 
1893 (Pinner, 1893; Pinner & Wolffenstein, 1891), and first synthesized chemically in 1903 
(Pictet, 1903), acts on various subtypes of nicotinic acetylcholine receptors (nAChRs) in the 
brain and in the periphery (Changeux, 2010; Langley, 1906).  
Besides tobacco, nicotine is found in plants of the nightshade family (solanaceae) such as 
tomato, potato, peppers and aubergine (eggplant) but also in tea plants (Schep et al., 2009). 
Accordingly, it is regularly taken up by the great majority of the human population with a 
mean daily dietary intake of approximately 1.4 µg per day (Siegmund et al., 1999). The 
alkaloid is readily absorbed by the lung or intestinal tissue, distributed by the blood and 
transported across the blood-brain barrier (Allen & Lockman, 2003; Oldendorf et al., 1979). 
When inhaled it takes about seven seconds for nicotine to reach the brain (Rose et al., 2010), 
where it binds with high affinity to the heteromeric ǂ4ǃ2 and the homomeric ǂ7 nAChRs, 
the two most abundant nAChR populations (Changeux, 2010). In the brain, nAChRs are 
involved in attention and cognition, locomotion, vigilance control, and rewarding 
mechanisms (Changeux, 2010; Graef et al., 2011), and they are suggested to play a major role 
in brain development (Hruska et al., 2009; Ross et al., 2010).  
Notably, nicotinic receptors, and in particular ǂ7 nAChR, are not only expressed on neurons 
but virtually on all cell types present in the brain including astrocytes (Sharma & 
Vijayaraghavan, 2001), microglia (De Simone et al., 2005; Suzuki et al., 2006), 
oligodendrocyte precursor cells (Sharma & Vijayaraghavan, 2002), and endothelial cells 
(Hawkins et al., 2005). Accordingly, neuronal and non-neuronal expression of ǂ7 nAChR 
has also been found in peripheral organs (Albuquerque et al., 2009; Sharma & 
Vijayaraghavan, 2002).  
Molecular imaging in vivo as considered in this review relates exclusively to the use of 
radiolabelled receptor ligands, although occasionally optical imaging has been used to 
investigate the cholinergic system (Prakash & Frostig, 2005). Molecular imaging of ǂ4ǃ2 
nAChR in vivo has recently been reviewed (Horti et al., 2010; Sabri et al., 2008). Therefore, 
the current review is focussed on neuroimaging of ǂ7 nAChRs. 
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2. Role of 7 nicotinic receptors in normal brain function 
ǂ7 nAChRs, discovered in 1990 (Couturier et al., 1990), belong to the superfamily of 
multisubunit ligand-gated ion channels and mediate the effects of the endogenous 
neurotransmitter acetylcholine. Homomeric ǂ7 nAChR is functionally distinct from the 
heteromeric nAChRs due to lower affinity to the agonists acetylcholine and nicotine, and 
higher affinity to the antagonistic snake venom ǂ-bungarotoxin (ǂ-BGT). Agonist binding 
induces a change in conformation of all five subunits of the ǂ7 nAChR and leads to opening 
of the cation-conducting channel across the plasma membrane, probably by cis-trans prolyl 
isomerisation (Lummis et al., 2005). Regarding ion selectivity, ǂ7 nAChR is known to have 
the highest permeability to Ca2+ ions within all nAChR subtypes (Dajas-Bailador et al., 2002; 
Gilbert et al., 2009; Sharma & Vijayaraghavan, 2001). Therefore, the activation of ǂ7 nAChR 
changes the intracellular Ca2+ homoestasis both directly as well as indirectly, the latter via 
voltage-dependent membrane-spanning Ca2+ channels as well as Ca2+ release channels and 
pumps in the endoplasmatic reticulum. Downstream events of this Ca2+ signalling result in 
(i) immediate effects, such as neurotransmitter release, (ii) short-term effects, such as 
receptor desensitisation and recovery, and (iii) long-lasting adaptive effects, such as 
neuroprotection or changes in the plasticity of the brain via gene expression (Leonard, 2003; 
Radcliffe & Dani, 1998; Shen & Yakel, 2009). Dependent on the cell-specific pattern of 
intracellular signalling in neurons with ǂ7 nAChRs located post-, pre- and extrasynaptically 
(Berg & Conroy, 2002; Frazier et al., 1998; Schilström et al., 2000), these complex functional 
properties explain the involvement of the ǂ7 nAChR in physiological processes of 

























Fig. 1. Involvement of ǂ7 nAChRs in physiological and pathophysiological processes of 
neurotransmission.  
For example, presynaptic ǂ7 nAChRs regulate, either directly or via modulation of 
glutamate release, the activity profiles of neurotransmitters such as GABA (Albuquerque et 
al., 1997; Liu et al., 2001), noradrenaline (Fu et al., 1999; Li et al., 1998), or dopamine (Kulak 
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et al., 1997; Northrop et al., 2010) and thereby mediate neuronal adaptation related to 
development, learning, memory, attention, pain perception, and reward. Furthermore, ǂ7 
nAChRs mediate postsynaptic responses in serotonergic neurons involved in maintaining 
the waking state (Galindo-Charles et al., 2008). An assumed contribution of ǂ7 nAChRs to 
the formation of endocannabinoids (Stella & Piomelli, 2001) and a proposed regulation of ǂ7 
nAChR activity by anandamide (van der Stelt & Di Marzo, 2005) is consistent with a 
functional interaction of neuromodulating systems involved in drug dependency 
(McPartland et al., 2008). 
 
Species Brain region Radioligand, 
concentration 
Receptor binding* Referenz 
Human Nucleus 
reticularis 
[125I]ǂ-BGT, 1 nM 5-12 nM (Spurden et al., 1997) 
 Nucleus 
geniculatis lat.  
[125I]ǂ-BGT, 1 nM 
 
2 nM (Spurden et al., 1997) 
 Dorsolateral 
prefrontal cortex 
[125I]ǂ-BGT, 5 nM 9-12 nM (Mathew et al., 2007) 
 Cingulate cortex [125I]ǂ-BGT, 2.6 nM ~ 16 nM (Marutle et al., 2001) 
 Temporal cortex [125I]ǂ-BGT, 2.6 nM ~ 8 nM (Marutle et al., 2001) 
 Hippocampus [125I]ǂ-BGT, 1.2 nM 2-8 nM (Hellström-Lindahl & 
Court, 2000) 
 Cerebellum [125I]ǂ-BGT, 1 nM 1-3 nM (Lee et al., 2002)  
Monkey Cortex [125I]iodo-MLA 6 nM (Bmax)  (Kulak et al., 2006) 
 Striatum [125I]iodo-MLA 3-4 nM (Bmax)  (Kulak et al., 2006) 
  [125I]ǂ-BGT, 3 nM 7.5 nM (Quik et al., 2005) 
Rat Cortex [3H]MLA, 5 nM 6-16 nM (Mugnaini et al., 2002)  
  [3H]MLA, 20 nM ~30 fmol/mg protein (Davies et al., 1999) 
  [125I]ǂ-BGT, 10 nM ~40 fmol/mg protein (Davies et al., 1999) 
  [125I]ǂ-BGT ~ 1.1 nM (Bmax) (Christensen et al., 2010) 
 Thalamus [3H]MLA, 5 nM 0.9 - 21 nM (Mugnaini et al., 2002) 
 Hippocampus [3H]MLA, 5 nM 6-182 nM (Mugnaini et al., 2002) 
  [3H]MLA, 20 nM ~ 70 fmol/mg protein (Davies et al., 1999) 
  [125I]ǂ-BGT, 10 nM ~ 70 fmol/mg protein (Davies et al., 1999) 
  [125I]ǂ-BGT ~1.2 nM (Bmax)  (Christensen et al., 2010)  
 Hypothalamus [3H]MLA, 5 nM 14-34 nM (Mugnaini et al., 2002) 
  [3H]MLA, 20 nM ~ 55 fmol/mg protein (Davies et al., 1999) 
  [125I]ǂ-BGT, 10 nM ~ 50 fmol/mg protein (Davies et al., 1999) 
Mouse Cortex [3H]MLA, 2 nM 1-5 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]ǂ-BGT, 1.2 nM ~ 8 nM (Svedberg et al., 2002)  
  [125I]ǂ-BGT, 2 nM 0-3 fmol/mg protein (Whiteaker et al., 1999) 
 Thalamus [3H]MLA, 2 nM 1-20 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]ǂ-BGT, 2 nM 0-12 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]ǂ-BGT, 1.2 nM ~ 3 nM (Svedberg et al., 2002)  
 Hippocampus [3H]MLA, 2 nM 0-9 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]ǂ-BGT, 2 nM 0-4 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]ǂ-BGT, 1.2 nM ~ 12 nM (Svedberg et al., 2002)  
 Hypothalamus [3H]MLA, 2 nM 1-12 fmol/mg protein (Whiteaker et al., 1999) 
  [125I]ǂ-BGT, 2 nM 1-6 fmol/mg protein (Whiteaker et al., 1999) 
 
Table 1. Quantitative in vitro autoradiographic studies on ǂ7 nAChR binding of various 
radioligands in the brains of different species, *nM = fmol/mg wet weight 
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Qualitatively, the expression pattern of ǂ7 nAChR is similar in rodent and primate brain 
(Han et al., 2000), although a comprehensive and parallel quantitative analysis of ǂ7 nAChR 
protein expression in the brain of different species, expected to facilitate the translation of 
experimental data on the imaging of ǂ7 nAChR from in vitro and in vivo animal models into 
clinical application, is still warranted. In general, regions with high- to moderate-density of 
ǂ7 nAChR gene expression and [125I]ǂ-BGT binding are related to learning and memory 
such as thalamic and hippocampal structures, the horizontal limb of the diagonal band of 
Broca, and the nucleus basalis of Meynert (Alkondon et al., 2007; Breese et al., 1997; Fabian-
Fine et al., 2001; Hellström-Lindahl et al., 1999; Schulz et al., 1991; Spurden et al., 1997). 
However, species differences exist regarding the total number of binding sites of ǂ7 nAChR 
specific radioligands (Han et al., 2003) with for example a lower amount of [125I]ǂ-BGT 
binding in the monkey hippocampus or the human thalamus and cortex compared with the 
same regions of rat brain (Breese et al., 1997) (Tab. 1).  
3. Alterations of 7 nAChR in diseased brain  
The World Health Organization has classified dependence on the use of drugs including 
tobacco as a disease in 1965. During the following decades convincing evidence was 
obtained that nicotine is the key factor in tobacco addiction and that nicotinic acetylcholine 
receptors are of importance (Stolerman, 1990). It has been suggested that ǂ7 nAChRs in the 
ventral tegmental area mediate nicotine´s stimulatory effect on mesolimbocortical 
dopaminergic function and consequently its reinforcing and dependence-producing 
properties (Nomikos et al., 2000). As shown in rats, exposure to tobacco smoke not only 
induced nicotine dependence but increased the ǂ7 nAChR density in the CA2/3 area (+ 
25%) and the stratum oriens (+ 18%) of the hippocampus (Small et al., 2010). 
With respect to clinical considerations, a close association between nicotine addiction and 
schizophrenia has been found (Lohr & Flynn, 1992). Consistent with the hypothesis, that a 
gene-mediated dysfunction of ǂ7 nAChR (Dome et al., 2010; Freedman et al., 1997; Stephens 
et al., 2009) underlies impairments seen in schizophrenia (Nomikos et al., 2000),  the density 
of hippocampal [125I]ǂ-BGT binding sites was decreased in schizophrenic patients 
(Freedman et al., 1995) but was at control levels in schizophrenic smokers (Mexal et al., 
2010).  
Evidence for an involvement of ǂ7 nAChR in Alzheimer’s disease (AD) was obtained at 
about 30 years ago from data showing a significantly reduced number of [125I]ǂ-BGT 
binding sites in the mid-temporal gyrus from demented patients (Davies & Feisullin, 1981). 
During the last decade, comparable results were obtained by analysing other 
neurodegenerative diseases. Lewy body dementia (DLB) and Parkinson´s disease have also 
been associated with alterations in the transcription or translation of the ǂ7 subunit 
(Burghaus et al., 2003; Court et al., 2000; Nordberg, 2001; Wevers & Schröder, 1999), 
indicating a hypocholinergic tone due to for example reduced levels of ǂ7 mRNA and 
protein in the hippocampus and reticular nucleus in AD and DLB (Court et al., 1999; Guan 
et al., 2000; Hellström-Lindahl et al., 1999). Functional interactions of ǃ-amyloid with ǂ7 
nAChR, revealed in vitro (Wang et al., 2000), and the colocalization of both in AD support 
the hypothesis that neuronal degeneration in AD might also be triggered by ǃ-amyloid-
initiated and ǂ7 nAChR-mediated inflammatory processes (Bencherif & Lippiello, 2010). 
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Interestingly, also in traumatic brain injury (TBI), regarded as risk factor for AD (Fleminger 
et al., 2003), significantly lowered ǂ7 nAChR densities were found in rats and pigs 
(Hoffmeister et al., 2010). The resulting cholinergic hypofunction may attenuate the anti-
inflammatory effect of acetylcholine (Rosas-Ballina & Tracey, 2009) and thus contribute to 
the process of neurodegeneration (Conejero-Goldberg et al., 2008). 
Other diseases with potential involvement of ǂ7 nAChR include epilepsy and attention 
deficit hyperactivity disorder (ADHD). While some forms of epilepsy have recently been 
associated with alterations of ǂ4 subtype expression (Raggenbass & Bertrand, 2002), there is 
experimental evidence that ǂ7 nAChR may play a role in epileptogenesis (Dobelis et al., 
2003). Based on similarities between schizophrenia and ADHD with regard to a number of 
disturbances in attention it has been hypothesized that the ǂ7 subunit gene may be of 
significance in ADHD although experimental data are still missing (Kent et al., 2001). 
Previous attempts to treat ADHD patients with nicotine (Levin et al., 1996; Potter & 
Newhouse, 2004) are currently repeated in a Phase II study with the selective ǂ7 nAChR 
ligand TC-5619 by Targacept Inc.  
4. 7 nAChR as target for drug development 
Because the activation of ǂ7 nAChR persistently affects synaptic transmission, multiple 
neurotransmitter and neuropeptide systems, and eventually brain plasticity (Leonard, 2003; 
Radcliffe & Dani, 1998; Shen & Yakel, 2009), ǂ7 nAChR has been assessed as a potential 
target for the rational design of drugs for neuroprotective and neuropsychiatric indications. 
The large number of studies on receptor structure and pharmacology makes ǂ7 nAChR an 
extensively investigated receptor protein and the continued development of orthosteric 
ligands and allosteric modulators by the pharmaceutical industry testifies the importance of 
efforts to assess ǂ7 nAChR expression and functionality in the living human brain (Bunnelle 
et al., 2004; Mazurov et al., 2006). 
Evidence of a correlation between ǂ7 nAChR properties and brain performance has been 
provided by studies on the attentional and cognitive enhancement obtained by ǂ7 nAChR 
agonists (Feuerbach et al., 2009; Levin et al., 1999; Roncarati et al., 2009) and positive 
allosteric modulators (Faghih et al., 2008; Timmermann et al., 2007) as well as on ǂ7 nAChR 
related pharmacotherapeutic approaches for schizophrenia (Freedman et al., 2008; Olincy et 
al., 2006; Tregellas et al., 2011), and dementia (Bacher et al., 2010; Kitagawa et al., 2003; 
Thomsen et al., 2010). Furthermore, electrophysiological (Hurst et al., 2005; Ng et al., 2007) 
and behavioural data (Bitner et al., 2010; Pacini et al., 2010; Tietje et al., 2008) highlight the 
potential of ǂ7 nAChR as therapeutic target for neurodegenerative diseases. The close 
connection between ǂ7 nAChR signalling, inflammation, and neurodegeneration makes ǂ7 
nAChR auspicious also for medicinal control of inflammation as an epiphenomenon of 
many brain disorders (Conejero-Goldberg et al., 2008; de Jonge & Ulloa, 2007; Rosas-Ballina 
& Tracey, 2009). 
5. Noninvasive imaging of 7 receptors in normal and diseased brain 
Far beyond what can be analysed postmortem, the non-invasive and real-time investigation 
of ǂ7 nAChR by means of molecular imaging techniques provides the assessment of 
temporal and spatial changes in receptor distribution and density during disease 
progression and drug treatments.  
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5.1 Technical requirements 
The most advanced system for non-invasive diagnostic and therapeutic neuroreceptor 
imaging is positron emission tomography (PET) (Antoni & Langström, 2008; Hagooly et al., 
2008; Heiss & Herholz, 2006). In PET, the quantitative detection of the distribution of 
radiolabeled molecules in vivo with high resolution and sensitivity leads to functional 
images of brain biochemistry and physiology (Spanoudaki & Ziegler, 2008). PET has now 
become an advanced nuclear medicine imaging technique integrated into routine clinical 
use (Galban et al., 2010) and a highly sophisticated tool for experimental animal research 
(Lancelot & Zimmer, 2010; Xi et al., 2011). 
Receptor ligands used for PET are radiolabelled with short-lived positron-emitting isotopes 
such as 15O, 13N, 11C, and 18F with half-lives of 2, 10, 20.4, and 109.6 min, respectively. The 
spatial resolution of recently developed clinical PET systems with about 2-3 mm allows 
tracing of radioligand distribution even within small cerebral nuclei in human brain (Heiss 
et al., 2004; Lecomte, 2009; Wienhard et al., 2002), and a detailed regional analysis also in 
rodents (Lancelot & Zimmer, 2010; Lecomte, 2009; Xi et al., 2011) can be achieved with 
dedicated small-animal PET scanners. To overcome the problem of the anatomic 
classification of areas with increased or diminished radioligand accumulation, co-
registration of brain anatomy with MRI or CT is needed. Software-based approaches used 
for computerized anatomical alignment have been very successful in brain imaging because 
of the relatively fixed and uniform structure of the head, and both manual and automated 
systems have been developed in the last years (Slomka & Baum, 2009). Through the use of 
multimodal approaches delineation of small-sized but receptor-rich brain areas is 
considerably improved (Heiss, 2009). During the last decade hybrid PET-CT scanners have 
been developed, where two gantries for PET and CT are placed back-to-back (Mawlawi & 
Townsend, 2009). Technically even more challenging is the development of hybrid PET-MRI 
scanners because of the sensitivity of the photomultiplier tubes of the standard PET 
detectors to even low magnetic fields. This problem has been solved only recently (Pichler et 
al., 2008; Pichler et al., 2006) and was first successfully accomplished for small-animal 
designs (Judenhofer et al., 2008). Very recently, fully integrated PET-MRI systems which 
allow simultaneous data acquisition have been developed as clinical research instruments, 
and four prototypes of integrated hybrid PET-MRI scanners were installed at two PET 
centres in Europe (Germany) and the United States so far. However, several technological 
and methodical issues have to be addressed before PET-MRI can establish itself as a routine 
clinical tool (von Schulthess & Schlemmer, 2009).  
5.2 Radiotracer development 
PET technology, using radionuclides with high specific radioactivity and the opportunity to 
specifically label a chemical compound by substituting a stable atom with its radioactive 
counterpart, combined with quantitative measurements of radioactivity, is the preferred 
modality for molecular imaging (Antoni & Langström, 2008). Despite of some of the 
limitations in instrumentation discussed above, the bottleneck for broad clinical applications 
in neuroimaging is the limited availability of suitable radioligands. Among positron-
emitting isotopes only 11C and 18F are applicable for imaging of neurotransmitter-related 
components in the brain. Their short half-live (11C: t1/2 = 20.4 min, 18F: t1/2 = 109.6 min) 
allows repeated investigations in the same patient or the same animal with short time 
intervals. Accordingly, the patient or the animal can be considered as its own reference 
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following a pharmacological intervention. For use in a satellite concept (i.e. with no on-site 
cyclotron available at the PET center), there is a special demand for PET radioisotopes with 
longer half-life such as 18F.  
Even though the basic mechanisms of radioligand-target interactions in vitro and in vivo are 
identical, in vivo imaging requires some additional factors that have to be taken into account. 
In addition to high-affinity binding and supreme selectivity towards the biological target, 
key requirements for all types of radioligands, suitable physicochemical properties gain 
special importance for brain imaging with PET. For example not only the transfer of the 
radioligand across the blood-brain barrier (BBB) is determined by its lipophilicity (Davson & 
Segal, 1996; Liu et al., 2010) but also the non-specific binding (Waterhouse, 2003). High 
accumulation and prolonged retention in the target region with target-to-background ratios 
of desirably more than 5 are closely related to both the affinity of the radioligand and the 
density of its potential binding sites, which are small compared to the concentration of non-
target proteins. Because saturation of binding sites may be obtained at comparably low 
radioligand concentrations, the concentration of the radioligand applied has to be about 
1000-fold lower than the pharmacological threshold. In other words, high specific activity in 
the range of 50-500 GBq/µmol has to be achieved, feasible nowadays with both 11C- and 18F-
labeled radioligands (Antoni & Langström, 2008).  
In summary, high target affinity, specificity, sensitivity, metabolic stability and appropriate 
pharmacokinetics are among the most important features for a good in vivo neuroreceptor-
imaging agent. Despite the fact that over the past decade a great variety of ǂ7 nAChR 
selective agents have been developed, so far there are only a few radioligands which fulfil at 
least some of these criteria and will be discussed below.  
5.3 Imaging of 7 nAChR in animal and human brain  
Although a radiopharmaceutical for PET imaging of ǂ7 nAChR that fulfills all the above-
mentioned pre-conditions is still missing, there is general agreement to develop ligands, 
which bind to the orthosteric site of the ǂ7 nAChR. The steric and electronic requirements of 
this site are met by structurally diverse classes of compounds as reviewed recently 
(Toyohara et al., 2010a), and potential ligands originate from for example benzylidene 
anabasein compounds such as GTS-21 (Meyer et al., 1998), or the quinuclidine framework 
such as AR-R-17779, both shown in Fig. 2 (Bodnar et al., 2005; Mazurov et al., 2005; Mullen 
et al., 2000; Tatsumi et al., 2005). A recently developed highly selective fluorescent ǂ7 
nicotinic receptor ligand is restricted to in vitro studies because of its chemical structure 
(Hone et al., 2010). 
Despite this basic knowledge and promising experimental data obtained in vitro, the 
imaging of ǂ7 nAChR in vivo is still in its infancy. This is not only due to the inadequate in 
vivo performance caused by an insufficient target specificity of radioligands such as the non-
negligible 5HT3R binding of otherwise promising quinuclidine-based tracers (Pomper et al., 
2005) (Table 2). 
Compared to the heteromeric ǂ4ǃ2 nAChRs, imaging of ǂ7 nAChR is challenged by the 
much lower expression of this target, which is illustrated by the up to 100-fold lower density 
of binding sites of ǂ7-specific [125I]ǂ-BGT in comparison to ǂ4ǃ2-specific [3H]nicotine in 
different nuclei of human thalamus (Spurden et al., 1997). Furthermore, the outcome of 
preclinical studies in primates can hardly be predicted from biodistribution studies in 
rodents. While in the monkey brain high target-to-nontarget ratios were obtained for the 
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diazabicyclooctane derivatives [11C]A-582941 and [11C]A-844606, both failed with regard to 
regional distribution and selectivity in the mouse brain (Toyohara et al., 2010b) (Tab. 2).  
 
 
Fig. 2. Lead structures for development of radioligands for neuroimaging of ǂ7 nAChR 
Recently, the 1,4-diazabicyclo-[3.2.2]nonane skeleton (Bunnelle et al., 2004) has been 
identified as new structure to improve the receptor-ligand interaction, and both 18F-
substituted compounds such as [18F]NS10743 (Peters et al., 2007) and those for labelling with 
11C such as [11C]CHIBA-1001 (Hashimoto et al., 2008; Toyohara et al., 2009) and 
[11C]NS12857 (Lehel et al., 2009) have been designed (Table 2). As illustrated by the data in 
Tab. 2, the general suitability of these derivatives for imaging of ǂ7 nAChR is supported by 
preclinical PET studies in pigs (Deuther-Conrad et al., 2011; Lehel et al., 2009) and non-
human primates (Hashimoto et al., 2008) as well as a first clinical study (Toyohara et al., 
2009). However, substantial enhancement in the affinity of the ǂ7 nAChR PET ligands is 
required to improve image analysis, modelling, and eventually quantification of ǂ7 nAChR 
in brain diseases. Considering the low density of ǂ7 nAChR in brain, the target affinity of 
the currently most promising tracers [11C]CHIBA-1001 (Ki ~ 35 nM; (Hashimoto et al., 2008; 
Toyohara et al., 2009) and [18F]NS10743 (Ki ~ 10 nM; (Deuther-Conrad et al., 2009) has 
proved insufficient, because dissociation constants of ≥ 10 nM result in baseline binding 
potential values considerably lower than the threshold value of 2 (Koeppe, 2001). NS14490, a 
novel diazabicyclononane derivative which has been developed by NeuroSearch and 
radiolabelled in collaboration with the authors, possesses a Ki value of ~ 3 nM in vitro 
(Deuther-Conrad and colleagues, unpublished), and the ligand distribution pattern of 












Fig. 3. In vitro autoradiography on the distribution of [18F]NS14490 in rat brain (sagittal 
slices, 12 µm). A = [18F]NS14490, total binding; B = Co-incubation of [18F]NS14490 with 20 
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CD1 mice  
Biodistribution 
Very limited uptake of radioactivity 
in the brain; 
No evidence of receptor blockade 












SPRD rats  
Biodistribution
No regionally selective or specific 
binding 









High uptake in the pig brain; 
Distribution as reported in primates;
Lack of in vivo displacement 











High uptake in the pig brain; 
Blocking significantly reduced 
binding potential in regions with 
high radioactivity uptake 
(Deuther-Conrad 






Papio anubis  
Dynamic PET 
scan 
Very high initial uptake followed by 
rapid clearance; Radiometa-bolites 
penetrate the BBB;  
High nonspecific binding consistent 
with the low affinity for ǂ7 nAChR 







[11C]MeQAA Macaca mulatta 
Dynamic PET 
scan 
R-enantiomer with high uptake of 
radioactivity in the brain and ǂ7 
nAChR-related distribution 












Substantial and heterogenous brain 
accumulation;  
Uptake reduced to background level 
of the cerebellum by pretreatment 
with the ǂ7 nAChR agonist 
SSR180711 













Regional distribution consistent with 
ǂ7 nAChR expression 
 













Selective uptake in the regions of the 
hippocampus, cortex and basal 
ganglia; gradual washouts; 
cerebellum with lowest binding  
(Toyohara et al., 
2009) 
Table 2. Findings on in vivo biodistribution and PET imaging studies on the binding of ǂ7 
nAChR specific radioligands in brain of different species.  
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6. Noninvasive imaging of 7 nAChR in other diseases – Reality and vision  
For another derivative, NS14492, an IC50 value of 4.5 nM was reported. It was radiolabelled 
with 11C and investigated in pigs, where the radioligand showed the capability of measuring 
in vivo occupancy at 7 nAChR (Ettrup et al., 2010). 
With regard to molecular imaging, the development of quantitative approaches to visualise 
ǂ7 nAChR outside the brain is another big challenge because comparably low receptor 
densities have to be expected also in peripheral organs. Experimental radiotracer studies 
discussed above provided evidence of specific ǂ7 receptor binding not only in the adrenals 
with reported receptor densities of less than 10 fmol/mg in human tissue (Mousavi et al., 
2001) but also in heart, muscle, gut, kidney, thymus, pancreas and liver (Deuther-Conrad et 
al., 2009).  
In general, imaging the concentration, distribution and occupancy of neuroreceptors 
involved in respiratory and cardiovascular disorders is a very attractive research area as it 
can provide new insights in the aetiology of these diseases as well as means to diagnose 
them (Hagooly et al., 2008). Regarding ǂ7 nAChR, the presence of these receptors in 
microvascular endothelial cells has been shown and their involvement in the regulation of 
microvascular permeability and angiogenesis has been suggested (Egleton et al., 2009; Li & 
Wang, 2006; Moccia et al., 2004). 
Furthermore, nicotinic ǂ7 receptors are part of a neural circuit where acetylcholine 
transmitted via the vagus nerve is thought to control cytokine release as part of the 
cholinergic anti-inflammatory pathway (Tracey, 2002). This pathway may protect organs 
such as heart or kidney from ischemic injury (Li et al., 2010; Sadis et al., 2007; Yeboah et al., 
2008) and could be of importance in patients with autoimmune diseases known to be 
characterized by suppressed vagus nerve activity (Bruchfeld et al., 2010). Accordingly, 
neuroimmunomodulation mediated by ǂ7 nAChR agonists is regarded as a future 
therapeutic approach (Bencherif et al., 2011; Kumar & Sharma, 2010). 
Nicotinic ǂ7 receptors are also regarded as a powerful regulator of responses that stimulate 
cancer cells (Egleton et al., 2008; Schuller, 2009). In particular, evidence of the involvement 
of nicotinic ǂ7 receptors in the control of basal cell proliferation and differentiation 
pathways in lung and the participation of these receptors in airway remodelling during 
brochopulmonary diseases led to the assumption that ǂ7 nAChRs are of relevance for lung 
development, injury, repair, and carcinogenesis (Maouche et al., 2009). Because the ǂ7 
nAChR is the most predominantly expressed nAChR subtype in bronchial epithelial cells 
(Paleari et al., 2009) and mRNA for ǂ7 nAChR has been detected not only in normal lung 
cells but in most human lung cancer cell lines (Egleton et al., 2008; Plummer et al., 2005), it 
has been hypothesized that a desensitization of ǂ7 nAChR in heavy smokers with a 
prolonged exposure to nicotine could lead to squamous metaplasia (Tournier & Birembaut, 
2011). While in an early investigation of small cell carcinomas of the lung no specific [125I]-ǂ-
bungarotoxin binding could be demonstrated, probably due to a sub-threshold density of 
the ǂ7 receptor protein related to this particular type of cancer (Cunningham et al., 1985),  
not only all of 50 investigated non-small cell lung cancer (NSCLC) cell lines expressed the ǂ7 
subtype (Paleari et al., 2009) but also all out of 52 investigated NSCLC patients expressed ǂ7 
receptor mRNA and protein and the values were higher in smoking patients with squamous 
carcinomas than those with adenocarcinomas (Paleari et al., 2008).  
Besides lung cancer, ǂ7 nAChR-mediated signalling has been implicated in the growth and 
metastasis of colon cancer (Wei et al., 2009; Wei et al., 2011; Ye et al., 2004), probably due to 
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the activity of the endogenous allosteric ǂ7 nAChR modulator SLURP-1 and the 
upregulation of the downstream signalling molecule NF-κB (Chernyavsky et al., 2010; 
Pettersson et al., 2008; Ye et al., 2004). Also the development of keratinocyte carcinoma, the 
most prevalent skin cancer and the most common cancer in United States (Albert & 
Weinstock, 2003), may depend on ǂ7 nAChR expression and regulation. Interestingly, 
antagonisation of nAChR activity by SLURP-1 and -2 prevented the tobacco nitrosamine-
induced malignant transformation of oral keratinocytes (Arredondo et al., 2007), cells 
known to express ǂ7 nAChR (Chernyavsky et al., 2010). Further cancers with known ǂ7 
nAChR expression include breast, pancreas, and prostate carcinomas (Al-Wadei et al., 2009; 
Dasgupta et al., 2009; Hirata et al., 2010; Hruska et al., 2009). 
Based on this evidence, ǂ7 nAChR is considered a primary target in ongoing research on 
pathogenesis of a variety of cancers. Furthermore, the quantitative imaging of disease-
related changes in the expression of peripheral ǂ7 nAChR by PET is highly desirable for the 
validation of novel approaches in diagnostics and development of cancer-specific therapy.  
7. Conclusion 
Generally, the development of imaging approaches to non-invasively quantify ǂ7 nAChR 
receptors in and outside the brain is expected to help in the generation and testing of novel 
hypotheses supporting the understanding of pathogenetic processes and promoting novel 
diagnostic and therapeutic concepts. The clinical significance of a malfunction of ǂ7 nAChR, 
involved in particular cell-type and pathology specific modulating and signalling cascades, 
can be assessed on molecular level with an imaging-supported spatiotemporal 
quantification of ǂ7 nAChR protein. In this context, the imaging technique must be sensitive 
enough not only to identify but also to assess the dynamics and quantity of even subtle 
changes in the amount of functional ǂ7 nAChR, which is despite its physiological 
importance expressed at comparably low levels in the brain and periphery. PET techniques 
offer the highest achievable resolution of functional processes in the body in four 
dimensions by imaging of ǂ7 nAChR with further optimised PET radiotracers, which might 
be based for instance on the currently most promising diazabicyclononane derivatives.  
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